NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ:CLDA), which is focused on developing new predictive tests and targeted therapeutics from its growing portfolio of proprietary genetic biomarkers, today announced that it has made a milestone payment to Merck KGaA of Darmstadt, Germany in connection with its recently completed successful pivotal Phase III study of Vilazodone, a dual serotonergic antidepressant. Clinical Data’s PGxHealth Division acquired the rights to develop and commercialize Vilazodone from Merck in September 2004. Under the terms of the agreement, Clinical Data issued 135,146 shares of Clinical Data Common Stock. All of the shares issued to Merck are unregistered but carry certain demand and incidental registration rights as provided under the agreement.
